Monoclonal Antibody Highly Effective in Phase III Psoriasis Trial

(MedPage Today) -- The monoclonal antibody bimekizumab was more effective than ustekinumab (Stelara) or placebo for moderate-to-severe plaque psoriasis in a phase III trial, investigators reported.
At week 16, a 90% improvement on the Psoriasis...